ArticleThe Journal of investigative dermatology2014
Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.
Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Multilayered control of mRNA delivery to cell protrusions drives localized mini-cytoplasm establishment for stress-induced cell activation.Nature communications · 2026Article
- Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy.Annals of surgical oncology · 2021Article
- Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.Drug design, development and therapy · 2021Review
- Topical and intralesional therapies for in-transitmelanoma.Melanoma management · 2019Review
- Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study.Dermatology and therapy · 2018Article
- Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity.Frontiers in immunology · 2018Review
- Debunking the Myth of Exercise-Induced Immune Suppression: Redefining the Impact of Exercise on Immunological Health Across the Lifespan.Frontiers in immunology · 2018Review
- Epidermal cornification is preceded by the expression of a keratinocyte-specific set of pyroptosis-related genes.Scientific reports · 2017Article
- TSeminars in immunopathology · 2017Review
- Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.Experimental dermatology · 2016Article
- The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases.The Journal of allergy and clinical immunology · 2016Article
- Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin.Experimental dermatology · 2015Article
- Common clonal origin of central and resident memory T cells following skin immunization.Nature medicine · 2015Article
- Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.F1000Research · 2015Article
- Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. It is used as an immune-modulating therapeutic, but its molecular effects in human skin are largely unknown. We studied cellular and molecular characteristics of a recall response to 0.04% DPCP at 3-day (peak) and 14-day (resolution) time points using immune markers, reverse-transcriptase-PCR (RT-PCR), and gene array approaches. A peak response showed modulation of ∼7,500 mRNA transcripts, with high expression of cytokines that define all major effector T-cell subsets. Concomitant increases in T-cell and CD11c+ dendritic cell (DC) infiltrates were measured. The resolution reaction was characterized by unexpectedly high levels of T cells and mature (DC-lysosome-associated membrane glycoprotein positive (DC-LAMP+)) DCs, but with marked decreases in expression of IL-2, IFNγ, and other T cell-derived cytokines. However, negative immune regulators such as IDO1 that were high in peak reactions, continued to have high expression in resolution reactions. In the resolution reaction, ∼1,500 mRNA transcripts were significantly different from placebo-treated skin. These data suggest that the response to DPCP evolves from an inflammatory/effector peak at day 3 to a more regulated immune response after 14 days. This model system could be useful for further dissection of mechanisms of immune activation or negative immune regulation in human skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.